Author

Joshua Reardon

Observed names: J. Reardon, Reardon, J., Reardon, Joshua

Institution: Columbus Oncology and Hematology Associates

Observed institutions: The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University Wexner Medical Center, Columbus Oncology and Hematology Associates, The Ohio State University

ORCID: 0000-0002-7722-2360

Observed ORCID: 0000-0002-7722-2360

OpenAlex ID: A5085166382

Neoadjuvant Modified (m) FOLFIRINOX for Locally Advanced Unresectable (LAPC) and Borderline Resectable (BRPC) Adenocarcinoma of the Pancreas

2014 · Marlo Blazer, Christina Wu, et al. · Annals of Surgical Oncology · 244

A modified regimen of biweekly gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer is both tolerable and effective: a retrospective analysis

2016 · Daniel H. Ahn, Kavya Krishna, et al. · Therapeutic Advances in Medical Oncology · 59

Comparison of conventional versus liposomal irinotecan in combination with fluorouracil for advanced pancreatic cancer: a single-institution experience

2019 · Justin C. Tossey, Joshua Reardon, et al. · Medical Oncology · 24

Gemcitabine-Associated Thrombotic Microangiopathy: Response to Complement Inhibition and Reinitiation of Gemcitabine

2016 · Jeffrey L. Turner, Joshua Reardon, et al. · Clinical Colorectal Cancer · 24

Implementation and early outcomes for a surgeon‐directed hepatic arterial infusion pump program for colorectal liver metastases

2018 · Jeffery Chakedis, Eliza W. Beal, et al. · Journal of Surgical Oncology · 20

Pertuzumab for the treatment of patients with previously untreated HER2-positive metastatic breast cancer

2012 · Smith, M.B., Reardon, J., et al. · Drugs of today · 16

First-line gemcitabine plus nab-paclitaxel versus FOLFIRINOX for metastatic pancreatic cancer in a real-world population

2022 · Alycia Hatashima, Matthew J Arango, et al. · Future Oncology · 10

Successful Completion of Adjuvant Chemotherapy in a Patient With Colon Cancer Experiencing 5-Fluorouracil–Induced Cardiac Vasospasm

2015 · Craig A. Vargo, Marlo Blazer, et al. · Clinical Colorectal Cancer · 8

Antiemetic Control with Palonosetron in Patients with Gastrointestinal Cancer Receiving a Fluoropyrimidine-Based Regimen in Addition to Either Irinotecan or Oxaliplatin: A Retrospective Study

2012 · Marlo Blazer, Gary Phillips, et al. · Oncology · 2

Modified irinotecan and infusional 5-fluorouracil (mFOLFIRI) in patients with refractory advanced pancreas cancer (APC): a single-institution experience

2016 · M. Bupathi, D. H. Ahn, et al. · Medical Oncology · 1

Biweekly gemcitabine and low-dose cisplatin in the treatment of locally advanced or metastatic pancreatic cancer patients: a single institute experience

2015 · Jordan Lundberg, Joshua Reardon, et al. · Medical Oncology · 1

Antiemetic control of palonosetron in patients with gastrointestinal cancer receiving a fluoropyrimidine-based regimen containing either irinotecan or oxaliplatin.

2011 · M. A. Blazer, J. Reardon, et al. · Journal of Clinical Oncology

Works count: 13

Citation count: 409

H-index: 8

I10-index: 7